Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy

Recent studies suggest that thiazolidinediones ameliorate diabetic nephropathy (DN) independently of their effect on hyperglycemia. In the current study, we confirm and extend these findings by showing that rosiglitazone treatment prevented the development of DN and reversed multiple markers of oxid...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Zhang, Hongyu, Saha, Jharna, Byun, Jaeman, Schin, MaryLee, Lorenz, Matthew, Kennedy, Robert T., Kretzler, Matthias, Feldman, Eva L., Pennathur, Subramaniam, Brosius, Frank C.
Format: Artigo
Jezik:Inglês
Izdano: American Physiological Society 2008
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2576144/
https://ncbi.nlm.nih.gov/pubmed/18667486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajprenal.90208.2008
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki